OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
20/06/2025
Voltar para busca
Dado oficial do USPTO
VOHPANZ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
24
Atualização mais recente
21/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 44
Data de depósito
05/09/2023
Data de registro
26/03/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/03/2024
Última transação
21/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
MORAN, CAROLINE
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceutical products; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations for the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; dermatological pharmaceutical preparations; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; biological preparations for the treatment of bacterial infectionsviral infectionsinflammatory disordersfungal infectionscardiovascular diseases and disordersdermatological conditionsrespiratory diseases and disorderscentral nervous system diseases and disordersgastrointestinal diseases and disorderskidney diseasesdiabeteshypertensionskin disorderscancer and tumorsallergiesbone diseasesdiseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; biological preparations for use in hematology and in tissue and organ transplantation; biological preparations for prevention and treatment of eye diseases and conditions; biological preparations for the prevention and treatment of heart rhythm disorders; biological preparations for the prevention and treatment of immune system related diseases and disorders and stem cells for pharmaceutical and medical use
Classe 44
Collection and preservation of blood; Collection and preservation services for tissue and cellscollection and banking of umbilical cord tissue perivascular stem cells; medical diagnosis services; medical treatment services; provision of medical information and data for diagnosis and medical treatment
Publicações
Histórico de despachos e eventos da marca no USPTO.
24 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/03/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
18/03/2025
GPNX
NOTIFICATION PROCESSED BY IB
02/06/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
29/04/2024
FIMP
FINAL DISPOSITION PROCESSED
29/04/2024
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
25/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
26/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
26/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/01/2024
PUBO
PUBLISHED FOR OPPOSITION
09/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/12/2023
DOCK
ASSIGNED TO EXAMINER
04/12/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/11/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/11/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/11/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/11/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/11/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/11/2023
MAFR
APPLICATION FILING RECEIPT MAILED
31/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/10/2023
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
25/10/2023
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
19/10/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VOHPANZ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.